Neuromod Devices has announced the formation of a global commercial leadership team to further commercialise its Lenire tinnitus treatment device through key partnerships.
The team’s establishment sees the organisation’s U.S. executives Tish Ramirez, Holly Dean and Stephanie Glowacki join the existing commercial leadership team to establish a cross-functional group with significant sales, marketing, finance and clinical experience in hearing healthcare. The team’s strategy will support existing clinical partners to continue achieving successful treatment outcomes through further clinical and commercial initiatives while partnering with key specialists to introduce Lenire in new markets.
In addition to his role as CEO of Neuromod USA Inc., Eric Timm has been appointed President, Global Commercial Operations to head the team with global responsibility for its commercial strategy.
Mr. Timm has more than 35 years’ experience holding leadership positions in medical devices and hearing aid companies. He joined Neuromod in 2021 from WS Audiology, where he was President and Chief Executive Officer of the company’s U.S. wholesale business.
“Since joining Neuromod, I’ve seen first-hand the tremendous outcomes tinnitus patients have achieved using Lenire. I look forward to working with our commercial team to make that a reality for more people”, says Eric Timm.
This follows the launch of Lenire in Spain in March. Neuromod has partnered with TRUSBIN, a medical distribution company, to exclusively distribute Lenire in the country. Otorhinolaryngologist Dr Jordi Coromina of the Teknon Clinic in Barcelona is the first clinician in Spain providing treatment with the device as part of the deal.
“I’m delighted that by working with TRUSBIN we can make Lenire available to people living with tinnitus in Spain. We’re looking forward to continually expanding the availability of Lenire throughout the country,” explained Dr Ross O'Neill, Founder and CEO of Neuromod Devices.